A new immune-blocking therapy plus antibiotics for severe sepsis and ARDS in older adults
An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients
This project is trying a treatment that restores a natural TREM1 blocker together with antibiotics to help older adults with life-threatening bacterial sepsis or ARDS.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioprovar Corporation NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11370765 on NIH RePORTER |
What this research studies
If I had severe sepsis or ARDS, this project is trying to develop a treatment that combines a natural immune blocker called TREM1-sv with antibiotics to calm the harmful overactive inflammation. The team discovered TREM1-sv and saw much better survival in mice with severe bacterial infection when it was given with antibiotics, and they will use this grant to refine the drug, study safety and dosing, and meet regulatory requirements. The work includes more lab and animal testing, drug manufacturing under clinical standards, and preparation for human testing. If human trials start, patients would likely be enrolled through hospital intensive-care units that treat sepsis and ARDS.
Who could benefit from this research
Good fit: Ideal candidates would be older adults hospitalized with severe bacterial infections causing sepsis or acute respiratory distress syndrome who meet hospital trial enrollment criteria.
Not a fit: People with ARDS or respiratory failure caused by non-bacterial causes (for example viral or noninfectious injury), those not requiring intensive care, or those with contraindications to the therapy are unlikely to benefit.
Why it matters
Potential benefit: If successful, this approach could reduce the deadly inflammatory response and lower deaths from bacterial sepsis and ARDS in older adults when given alongside antibiotics.
How similar studies have performed: Targeting TREM1 and related immune pathways has shown promising results in animal studies but clinical proof of benefit in humans is limited or not yet established.
Where this research is happening
Houston, United States
- Bioprovar Corporation — Houston, United States (Active)
Researchers
- Principal investigator: Roussel, Eugene — Bioprovar Corporation
- Study coordinator: Roussel, Eugene
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.